These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 28751261)

  • 1. Getting a molecule into the clinic: Nonclinical testing and starting dose considerations.
    Baldrick P
    Regul Toxicol Pharmacol; 2017 Oct; 89():95-100. PubMed ID: 28751261
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nonclinical & clinical interface - extrapolation of nonclinical data to support Phase I clinical studies.
    Baldrick P; Reichl A
    Regul Toxicol Pharmacol; 2021 Apr; 121():104869. PubMed ID: 33482290
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Considerations for the nonclinical safety evaluation of antibody drug conjugates for oncology.
    Roberts SA; Andrews PA; Blanset D; Flagella KM; Gorovits B; Lynch CM; Martin PL; Kramer-Stickland K; Thibault S; Warner G
    Regul Toxicol Pharmacol; 2013 Dec; 67(3):382-91. PubMed ID: 24012707
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overview of the nonclinical quality and toxicology testing for recombinant biopharmaceuticals produced in mammalian cells.
    Lebrec H; Narayanan P; Nims R
    J Appl Toxicol; 2010 Jul; 30(5):387-96. PubMed ID: 20589744
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nonclinical development of biopharmaceuticals.
    Baumann A
    Drug Discov Today; 2009 Dec; 14(23-24):1112-22. PubMed ID: 19853058
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Considerations regarding nonhuman primate use in safety assessment of biopharmaceuticals.
    Buckley LA; Chapman K; Burns-Naas LA; Todd MD; Martin PL; Lansita JA
    Int J Toxicol; 2011 Oct; 30(5):583-90. PubMed ID: 22013138
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An Introduction to the Regulatory and Nonclinical Aspects of the Nonclinical Development of Antibody Drug Conjugates.
    Lansita JA; Burke JM; Apgar JF; Mounho-Zamora B
    Pharm Res; 2015 Nov; 32(11):3584-92. PubMed ID: 26108879
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibody Drug Conjugates: Nonclinical Safety Considerations.
    Hinrichs MJ; Dixit R
    AAPS J; 2015 Sep; 17(5):1055-64. PubMed ID: 26024656
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nonclinical strategy considerations for safety pharmacology: evaluation of biopharmaceuticals.
    Vargas HM; Amouzadeh HR; Engwall MJ
    Expert Opin Drug Saf; 2013 Jan; 12(1):91-102. PubMed ID: 23170873
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PEGylated Biopharmaceuticals: Current Experience and Considerations for Nonclinical Development.
    Ivens IA; Achanzar W; Baumann A; Brändli-Baiocco A; Cavagnaro J; Dempster M; Depelchin BO; Rovira AR; Dill-Morton L; Lane JH; Reipert BM; Salcedo T; Schweighardt B; Tsuruda LS; Turecek PL; Sims J
    Toxicol Pathol; 2015 Oct; 43(7):959-83. PubMed ID: 26239651
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current strategies in the non-clinical safety assessment of biologics: New targets, new molecules, new challenges.
    Brennan FR; Andrews L; Arulanandam AR; Blumel J; Fikes J; Grimaldi C; Lansita J; Loberg LI; MacLachlan T; Milton M; Parker S; Tibbitts J; Wolf J; Allamneni KP
    Regul Toxicol Pharmacol; 2018 Oct; 98():98-107. PubMed ID: 30026135
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunogenicity of biologically-derived therapeutics: assessment and interpretation of nonclinical safety studies.
    Ponce R; Abad L; Amaravadi L; Gelzleichter T; Gore E; Green J; Gupta S; Herzyk D; Hurst C; Ivens IA; Kawabata T; Maier C; Mounho B; Rup B; Shankar G; Smith H; Thomas P; Wierda D
    Regul Toxicol Pharmacol; 2009 Jul; 54(2):164-82. PubMed ID: 19345250
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High dose selection in general toxicity studies for drug development: A pharmaceutical industry perspective.
    Buckley LA; Dorato MA
    Regul Toxicol Pharmacol; 2009 Aug; 54(3):301-7. PubMed ID: 19477212
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Practical considerations for nonclinical safety evaluation of therapeutic monoclonal antibodies.
    Lynch CM; Hart BW; Grewal IS
    MAbs; 2009; 1(1):2-11. PubMed ID: 20046568
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nonclinical safety testing of biopharmaceuticals--Addressing current challenges of these novel and emerging therapies.
    Brennan FR; Baumann A; Blaich G; de Haan L; Fagg R; Kiessling A; Kronenberg S; Locher M; Milton M; Tibbitts J; Ulrich P; Weir L
    Regul Toxicol Pharmacol; 2015 Oct; 73(1):265-75. PubMed ID: 26219199
    [TBL] [Abstract][Full Text] [Related]  

  • 16. On setting the first dose in man: quantitating biotherapeutic drug-target binding through pharmacokinetic and pharmacodynamic models.
    Lowe PJ; Tannenbaum S; Wu K; Lloyd P; Sims J
    Basic Clin Pharmacol Toxicol; 2010 Mar; 106(3):195-209. PubMed ID: 20050847
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety Pharmacology of Anticancer Agents.
    Martin PL
    Handb Exp Pharmacol; 2015; 229():405-31. PubMed ID: 26091649
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nonclinical Safety and Toxicology.
    Stark C; Steger-Hartmann T
    Handb Exp Pharmacol; 2016; 232():261-83. PubMed ID: 26489827
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Projecting human pharmacokinetics of monoclonal antibodies from nonclinical data: comparative evaluation of prediction approaches in early drug development.
    Wang J; Iyer S; Fielder PJ; Davis JD; Deng R
    Biopharm Drug Dispos; 2016 Mar; 37(2):51-65. PubMed ID: 25869767
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Applicability of predictive toxicology methods for monoclonal antibody therapeutics: status Quo and scope.
    Kizhedath A; Wilkinson S; Glassey J
    Arch Toxicol; 2017 Apr; 91(4):1595-1612. PubMed ID: 27766364
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.